# Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

> **NCT00520481** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 41 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** IMC-A12 (Cixutumumab)

## Key facts

- **NCT ID:** NCT00520481
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2012-01
- **Final completion:** 2013-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2018-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520481, "Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00520481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*